Thrombotic microangiopathies: from empiricism to targeted therapies.
UPMC université Paris 6, AP-HP, hôpital Saint-Antoine, service d'hématologie et de thérapie cellulaire, Paris, France. paulcoppo@aol.com
Paul
P
Coppo
D051722:ADAM Proteins / Q000172:deficiency / Q000627:therapeutic use; D000071120:ADAMTS13 Protein; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D019348:Empiricism; D006463:Hemolytic-Uremic Syndrome / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D000069283:Rituximab; D054323:Shiga-Toxigenic Escherichia coli; D057049:Thrombotic Microangiopathies / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D014841:von Willebrand Factor / Q000378:metabolism
D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D014841:von Willebrand Factor; D000069283:Rituximab; C481642:eculizumab; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human